Efficacy of (R)-[11C] Verapamil-PET in diagnosis of Epilepsy(Year-Two)

Results We completed analyses in 20 patients with epilepsy, 8 of 12 patients with drug resistant epilepsy and 10 healthy controls. In the Drug resistant epilepsy group, 8 patients had a significantly larger extent of asymmetry between ipsilateral and contralateral areas compared to healthy controls. Also one of 8 patient with drug resistant epilepsy who had nonlesional frontal lobe epilepsy showed that increasing asymmetry of SUVs over the entire time checked by dynamic PET. In the Drug sensitive epilepsy group, there was no significant difference with healthy controls. From the results achieved so far, we confirmed importance of p-glycoprotein expression in drug resistant epilepsy by a noninvasive method. [11C]Verapamil PET can be used as a surrogate marker of p-glycoprotein expression in patients with epilepsy.